
Divestment of Nutrition Business to DANONE complete

Mumbai, July 26, 2012

We are pleased to advise that we have completed the transaction with DANONE for the divestment of the Nutrition Business.

With this closure, Wockhardt has received a consideration of Rs. 1280 crores.

With this, the net debt-equity of the company drops to less than 1

About Wockhardt

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland.

Wockhardt has a significant presence in USA, Europe and India, with 75% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 590 scientists, of whom 80 are doctorates. In all, Wockhardt has 158 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capabilities in all facets of development and manufacture of recombinant biopharmaceuticals.

Wockhardt boasts of a multi-ethnic workforce of more than 8000 people from 14 different nationalities.